Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor and Exhibitor Listing</td>
<td>7</td>
</tr>
<tr>
<td>Welcome from the President</td>
<td>10</td>
</tr>
<tr>
<td>Committee Listing</td>
<td>14</td>
</tr>
<tr>
<td>Chapter Executives</td>
<td>18</td>
</tr>
<tr>
<td>Continuing Nursing Education (CNE)</td>
<td>20</td>
</tr>
<tr>
<td>Program</td>
<td>23</td>
</tr>
<tr>
<td>Abstract Posters</td>
<td>29</td>
</tr>
</tbody>
</table>
Congratulations to the nominees of the 2021 Boehringer Ingelheim Oncology Nurse of the Year Award!

Toutes nos félicitations aux candidat(e)s au prix Boehringer Ingelheim de l’infirmier(ère) de l’année pour 2021!

Karina Black, Edmonton, AB
Ava Hatcher, Prince George, BC
Amber Killam, Ottawa, ON
Kathryn Nichol, Ottawa, ON

The award will be presented at the annual Awards of Excellence Ceremony at the CANO/ACIO 2021 Virtual Conference on Friday, October 22, 2021 from 12:00pm – 1:00pm EST.

Congratulations and best wishes to all nominees.

CANO/ACIO gratefully acknowledges the generous support of Boehringer Ingelheim (Canada) for this award

Le prix sera remis lors de la cérémonie annuelle de remise des prix d’excellence à la conférence virtuelle ACIO/CANO 2021 le vendredi 22 octobre 2021 de 12 h 00 à 13 h 00 HNE.

Encore une fois, toutes nos félicitations et nos meilleurs voeux à l’ensemble des candidates et candidats.

L’ACIO/CANO tient à remercier Boehringer Ingelheim (Canada) du généreux soutien fourni envers ce prix.
At Teva, we understand that nurses and countless other healthcare professionals serve a specific and important purpose throughout the patient treatment journey. We are committed to supporting nurses like you by producing biosimilars that you can trust. Because when you can feel confident in our products, your patients will share in that feeling.¹,²

When it comes to biosimilars, you can trust in Teva Canada as a key partner.

THE DIFFERENCE IS UNCOMPROMISED SAFETY

TAKE DRUG PROTECTION TO THE NEXT LEVEL WITH THE BD PHASEAL™ OPTIMA CLOSED SYSTEM TRANSFER DEVICE (CSTD)—helping to improve staff safety without compromising performance, ergonomics or ease of use. Its unique design features, such as our proprietary double membrane and vapor containment system, can help reduce the risk of hazardous drug surface contamination, as well as lower drug waste and residual drug loss. The injector component features a unique safety-forward design that keeps the needle encased when not activated, protecting your team from accidental needlesticks. Coupled with new value-add programs and exceptional clinical support, the BD PhaSeal™ Optima System allows you to make the most of departmental time and resources. Discover the next generation of hazardous drug protection.

Learn more about our drug waste reduction resources, hazardous drug detection programs and additional ways to optimize safety at bd.com/OptimaCSTD or contact us at 866.979.9408.

BD, the BD Logo and PhaSeal are trademarks of Becton, Dickinson and Company or its affiliates. © 2021 BD. All rights reserved. BD-44766 (09/21)
THE CANO/ACIO AWARDS CEREMONY IS SCHEDULED FOR
Friday, October 22, 2021 from 12:00pm - 1:00pm EST
during the CANO/ACIO 2021 Virtual Conference

At the ceremony we will recognize the extraordinary contributions of our members to their profession, their patients, and their community.

THE FOLLOWING AWARDS WILL BE PRESENTED:

- Boehringer Ingelheim Oncology Nurse of the Year Award
- Pfizer Award of Excellence in Nursing Clinical Practice
- Pfizer Award of Excellence in Nursing Education
- Pfizer Award of Excellence in Nursing Research
- Pfizer Award of Excellence in Nursing Leadership
- CANO/ACIO Award of Distinction
- CANO/ACIO Rising Star Award
- CANO/ACIO Research Grants
- CANO/ACIO Award for Excellence in Reviewing Peer Reviewed Manuscripts for CONJ
- CANO/ACIO Award for Best Manuscript in CONJ 2020-2021

OUR TWO LECTURESHP AWARDS WILL BE PRESENTED IN THE FOLLOWING SESSIONS:

**CLINICAL LECTURESHIP AND AWARD PRESENTATION**
Sunday, October 24, 2021 from 2:00pm – 2:45pm EST
Sponsored by Merck

**HELENE HUDSON LECTURE AND AWARD PRESENTATION**
Sunday, October 24, 2021 from 12:00pm – 12:45pm EST
Sponsored by AMGEN

We wish to thank members for the leadership shown in nominating one of their colleagues for an award.
And, we wish to thank the sponsors of the awards.
Sponsor and Exhibitor Listing

The 2021 CANO/ACIO Annual Virtual Conference is made possible by the generous support of the following organizations:

DIAMOND

Astellas Oncology, AstraZeneca, Janssen, Pfizer

PLATINUM

MERCK, AstraZeneca, BD, Jazz Pharmaceuticals, Teva Canada

GOLD

Apobiologix, ELVium Life Sciences, gsk, LA ROCHE-POSAY, VIATRIS

SILVER


BRONZE

SANOFI GENZYME, TAIHO

SYMPOSIA

Astellas Pharma Canada, Inc, AstraZeneca and Merck Canada, AstraZeneca Canada, Janssen, Jazz Pharmaceuticals, Teva Canada

FOCUS GROUPS

GSK, Pfizer Canada, Save Your Skin Foundation

PRODUCT THEATRE

Apobiologix, HANSamed Limited, Pfizer Canada

AWARD SPONSORS

Boehringer Ingelheim, Pfizer Canada, Amgen Canada, Merck Canada, CANO/ACIO

EXHIBITORS

This is how we define clinically meaningful

Outcomes that matter to patients

By developing novel targeted therapies, supporting promising research, and forming strategic collaborations with all members of the cancer community, Astellas Oncology is dedicated to moving cancer treatment forward for patients AND their loved ones.

Learn more at astellas.ca

© 2021 Astellas Pharma Canada, Inc. All rights reserved.
XTD_2021_0209_CA-EN 08/2021
Proud Supporter of the 2021 Canadian Association of Nurses in Oncology
Welcome from the President

Dear colleagues,

On behalf of the CANO/ACIO Board, I am excited to welcome you to our 33rd Annual CANO/ACIO Conference. Our conference theme, “I Am I Will: A Call to Action”, is particularly fitting this year, as we continue to navigate through the COVID-19 pandemic.

Throughout the pandemic, oncology nurses have enduringly demonstrated their commitment to quality patient care, education, research, and leadership. As I write this to you, we are now more than 19 months into this global pandemic and COVID-19 continues to permeate so much of our professional and personal lives. Healthcare has been unequivocally impacted, irrespective of practice setting and it is fair to say that no one in healthcare has been unaffected by COVID-19. As was discussed during last year’s conference, we know that people with cancer are at increased risk of severe outcomes after COVID-19 infection, including increased risk of death. In addition, people with cancer may not mount an effective immune response after COVID-19 vaccination. For these reasons, it is imperative that we do all that we can to protect those in our care and in our communities.

This year, we will host our second virtual conference. While there is no substitute for the connections and networking that occur with an in-person event, we are happy to report that our conference last year was well-attended and that we received an abundance of positive comments and feedback, particularly pertaining to the quality of content that was delivered. One of the silver linings of having to move to a virtual conference was that many nurses who would have otherwise been unable to attend our conference, were able to join, including nurses from Argentina and Venezuela. A highlight of last year’s conference was the keynote session presented by Dr. Sally Thorne entitled, “Nursing in Uncertain Times: The “Art” of Being a Nuisance”, a session that continues to hold relevance today and is well aligned with this year’s conference theme. As we have heard from many of you in our conference evaluations and membership surveys, there is a strong desire for oncology nurses to become more involved in advocacy, policy influence, and being a “nuisance”. It is, in some ways, serendipitous that the pandemic has forced the issue to some degree. Your CANO/ACIO Board has recognized this call to action and has responded accordingly. I will share a few examples of this below.

In late July, CANO/ACIO responded to Alberta’s plan to abandon the test, trace, isolate response to COVID-19 with a letter to the Alberta Minister of Health and the Chief Medical Officer of Health. We were compelled to respond because of the known risks of COVID-19 infection to people with cancer, including the increased risk of death. In early September, we issued a statement in support of mandatory COVID-19 vaccination for healthcare workers and participated in a video on the importance of COVID-19 vaccinations. In mid-September, we spoke out on the potential impact of postponed cancer surgeries on patients and their loved ones after many surgeries had to be rescheduled due to lack of ICU/critical care resources in Alberta’s hospitals.

As we look ahead, we can anticipate that there will be ongoing consequences of the COVID-19 pandemic on cancer care. Rates of cancer screening have been significantly lower during the pandemic compared to pre-pandemic times. For example, test volumes of cancer screening in Ontario were reduced by 41% in 2020 compared to 2019. Such changes in cancer screening may mean that people are diagnosed with later-stage disease and this may impact the curative potential of the disease. In addition, we know that some jurisdictions have had to postpone cancer surgeries, including diagnostic surgeries as well as surgeries intended as part of the cancer treatment. In addition to the potential for disease progression and subsequent increased pain and other symptoms, people whose cancer surgeries have been postponed are also dealing with significant psychosocial distress. Oncology nurses will inevitably rise to these challenges and continue to find ways to support people with cancer and their loved ones.

This year’s conference program is full of sessions that will address topics relevant for the practicing oncology nurse, educator, researcher, and leader. Similar to last year, conference sessions will be archived so that you may view them at a time that is convenient to you. We welcome everyone to attend our Annual General Meeting on Saturday, October 23 as the Board shares the work that has been done over the past year to achieve the goals established in our Strategic Plan (2017-2021) and looks ahead to 2022 and the development of our next Strategic Plan. The Annual General Meeting also serves as a forum for members to express their ideas.
and thoughts on how to move the Association forward. We need and value your participation and voice.

I would like to thank the Conference Planning Steering Committee, the Local Planning Committee, the Scientific Program Committee, the Recognition of Excellence Committee, and the Board of Directors for their hard work and efforts leading up to the conference. We would like to acknowledge all at Malachite Management and especially Dana Cooper and Ernest Ho for their tremendous efforts and diligence. Thank you to all of our conference sponsors, partners, and exhibitors. We are indebted to you for your support. Finally, we are so very grateful to all who participate in our conference, either as a speaker or as a delegate. Without your participation, this event would not be possible.

At a time when many in healthcare are exhausted and at risk of burnout, it is imperative that we attend to our physical and psychosocial well-being. I cringe a bit when I hear the term ‘self care’ as it puts the onus on individuals to take care of themselves. As nurses, I think we so often put the needs of others ahead of our own, making self-care seem somewhat foreign and even a bit uncomfortable. Rather than encouraging self-care, I implore each of you to instead check in on each other. Set up a Zoom coffee or wine date, connect over the phone, or even send an email to let someone know that you are thinking of them. Try to block off some time during the conference to connect with each other, if you can.

On behalf of the Board of Directors, it is our sincere wish that you enjoy our second virtual conference and that you find ways to connect with one another. Please reach out to any of us on the Board if we can be of help or even if you just want to chat. Finally, I would like to express my deepest gratitude to each of you for all that you have done and continue to do to improve the lives of all Canadians affected by cancer. You can and you have answered many calls to action in the past, and I have no doubt that you will continue to do so again and again.

With much love and respect always,

Reanne Booker, PhD(c), MN, NP
President, CANO/ACIO
Imagine a world where every lung cancer patient is screened before the disease spreads. Where every patient gets the right drug at the right time, and the goal of any treatment plan is to cure. Where every patient, everywhere in the world, can expect to receive the highest quality care that provides the best odds in the fight against the disease. **Where no patient dies from lung cancer.**

Together, AstraZeneca, the International Association for the Study of Lung Cancer, the Global Lung Cancer Coalition and Guardant Health have come to form the Lung Ambition Alliance. We share one goal: to double long-term survival in lung cancer by 2025. Through initiatives that increase early diagnosis, accelerate delivery of innovative precision medicines and improve quality care, we believe there is a way to solve the seemingly impossible and ultimately eliminate lung cancer as a cause of death.

Please visit LungAmbitionAlliance.org to know more about our first projects and help shape our priorities. Your insights will serve as an important first step on our life-changing journey toward accomplishing the impossible … together.

Join us at LungAmbitionAlliance.org.
Janssen Oncology
About the Janssen Pharmaceutical Companies of Johnson & Johnson

We’re the Pharmaceutical Companies of Johnson & Johnson. We focus on the following areas of medicine: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Visit [www.janssen.com/canada](http://www.janssen.com/canada) to learn more
Committee Listing

CONFERENCE PLANNING STEERING COMMITTEE / COMITÉ D’ORGANISATION DE LA CONFÉRENCE

Lorelei Newton, PhD, RN, CPSC Co-Chair
Simonne Simon, MN, CON(C), CPSC Co-Chair
Leslie Maskell, BA, RN, BScN, Con(C), 2021 LPC Co-Chair
Heidi Thomas, RN, BScN, CON(C), 2021 LPC Co-Chair
Janny Proba, RN, BScN, MEd(C), CON(C), CHPCN(C), CVAAC, 2021 SPC Co-Chair
Cheryl Page, RN, BScN, BSc, CON(C), BMTCN, 2021 SPC Co-Chair
Jodi Hyman, RN, BScN, CON(C), 2019 LPC Co-Chair
Rose Woloshyn, RN, BN, 2019 LPC Co-Chair
Michelle Rosentreter, RN, BN, CON(C), 2019 SPC Co-Chair
Kathleen Hennessey, RN, CON(C), CHPCN(C), 2022 LPC Co-Chair
Scott Beck, RN, BScN, 2022 LPC Co-Chair
Andrea Knox, RN, BSN, CON(C), 2022 SPC Chair

CANO BOARD OF DIRECTORS / CONSEIL D’ADMINISTRATION DE L’ACIO

Reanne Booker, RN, BScN, MN, NP
President / Présidente
Lorelei Newton, PhD, RN
Vice-President / Vice présidente
Simonne Simon, RN, MN, CON(C)
Treasurer / Trésorière
Kara Jamieson, RN, MN, MEd, CON(C)
Director—at–Large — Communications / Conseillère générale, communications
Sarah Champ, MN, RN, CON(C)
Director—at–Large — Education / Conseillère générale, education
Andrea Knox, RN, BSN, MSN, CON(C)
Director—at–Large — External Relations / Conseillère générale, relations extérieures
Jodi Hyman, RN, BScN, CON(C)
Director—at–Large — Membership / Conseillère générale, adhésion
Samantha Scime, RN, MN, CON(C)
Director—at–Large, Professional Practice / Conseillère générale, pratique professionnelle
Christine Maheu, RN, PhD
Director—at–Large — Research / Conseillère générale, recherché
Margaret Fitch, RN, PhD
Canadian Oncology Nursing Journal Editor—in–Chief / Revue canadienne de soins infirmiers en oncologie, éditeur en chef
Manon Lemonde, RN, PhD
Incoming Director—at–Large — Research / Conseillère générale entrant, recherché

SPECIAL INTERESTS GROUP

Jodi Hyman, RN, BScN, CON(C) (Chair)
Lisa Henczel, RN, BScN, MSN, NP(F)
Michelle Ellwood, RN
Cationa (Trina) Buick, RN, PhD
Kari Kolm, RN(ED), MN, NP
Kristine Leach, RN(EC), MN, CON(C)
Marcia Flynn-Post, RN, BA, MHS, CON(C)
Leslie Marvell, RN, BScN, CHPCN(C), CON(C)
Joy Tarasuk, RN, BScN, MN, CON(C)
Ruby Gidda, RN, BScN, M.Ed.
Jennifer Anderson, RN, MN, CON(C)
Allison Wiens, RN, BN
Fay Strohschein, RN, PhD
Amber Killam, RN, MSN, CON(C)
Renata Benc, BA, MSc(AIN), CON(C)
Anita Long, RN, MSN/EO, CON(C)
Tracyann Machado, RN
Carrie Liska, RN, MN, PhD(c)
Karina Bilodeau, RN, BScN, MScN, PhD CON(C)
Jill Bullock, RN, BScN, MN CON(C)

RECOGNITION OF EXCELLENCE COMMITTEE

Rana Jin, RN, MSN, CON(C) (Co-Chair)
Karen Janes, RN, BScN, MSN (Co-Chair)
Catherine Fox, MN, RN, CON(C)
Edith Pituskin, NP, PhD
Heather Brander, RN, BScN, CHPCN(C), CON(C)
Leah Lambert, RN, BScN
Lorelei Newton, PhD, RN

RESEARCH

Christine Maheu, RN, PhD (Chair)
Jill Bally, RN, PhD
Jacqueline Galica, RN, MSc, PhD, CON(C)
Kristen Haase, RN, PhD
Leah Lambert, RN, PhD
Virginia Lee, RN, PhD
Manon Lemonde, PhD, RN, CON(C)
Marian Florence Lucktart-Flude, RN, BScN, MSN, PhD, CCSNE
Samantha Mayo, RN, PhD
Tracy Powell, BScN, RN, MN, PhD(c)
Our goal is to offer smoke-free alternatives that have the potential to reduce the risk of developing smoking-related diseases as compared with continued smoking.

Recent advances in science and technology have made it possible to develop innovative products that current adult smokers accept and that are less harmful alternatives to continued smoking.

Rigorous, robust and transparent science is at the core of the development and assessment of our smoke-free products.

Our practices are inspired by the pharmaceutical industry and aligned with FDA’s Draft Guidance on Modified Risk Tobacco Products Applications.
FOR MEN WITH ADVANCED PROSTATE CANCER

Up to 1 in 5 men have a distinct disease hiding in plain sight\textsuperscript{1-6}

Have you tested your patients for \textit{BRCA} and \textit{ATM} mutations?

\textit{BRCA} and \textit{ATM} are part of a family of genes involved in DNA damage repair.\textsuperscript{1,5}

Prostate cancer with mutations in the \textit{BRCA} and \textit{ATM} genes results in a more aggressive disease, leading to a decrease in patient survival.\textsuperscript{1-3,7-10}

Consider testing for \textit{BRCA} and \textit{ATM} mutations in all men with advanced prostate cancer to inform prognosis, predict response to novel targeted therapies and assess familial cancer risk.

DISCOVER MORE: testprca.ca

\textit{ATM}=ataxia-telangiectasia mutated; \textit{BRCA}=breast cancer 1/breast cancer 2
 Vyxeos® (daunorubicin and cytarabine liposome for injection) is indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults.¹

For more information:
Consult the Vyxeos Product Monograph at: www.jazzpharma.com for important information relating to adverse reactions, drug interactions, and dosing information that have not been discussed in this piece.
The Product Monograph is also available by calling our medical department at: 1-800-520-5568.

ZEPZELCA™ (lurbinectedin) is indicated for the treatment of adult patients with Stage III or metastatic small lung cancer (SCLC) who have progressed on or after platinum-containing therapy.²
This indication has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization.²

For more information:
Consult the ZEPZELCA Product Monograph at: www.jazzpharma.com for important information relating to adverse reactions, drug interactions, and dosing information that have not been discussed in this piece.
The Product Monograph is also available by calling our medical department at: 1-800-520-5568.

REFERENCES:

Vyxeos® is a registered trademark of Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals subsidiary)
ZEPZELCA™ is a trademark of Pharma Mar, S.A. used by Jazz Pharmaceuticals under license.
©2021 Jazz Pharmaceuticals, Inc. All rights reserved.

CA-VYX-2100066
Chapter Executives

**BC CHAPTER**
Andrea Knox, President
Michelle LaFreniere, Past President
Suzanne Daniel, Vice President
Karen Janes, Secretary
Senz Hamilton, Treasurer
Andrea Knox, Membership & Communications

**NORTHWEST TERRITORIES CHAPTER**
Catherine Dixon, President
Julie Jones, Vice President/Treasurer
June Bartlett, Secretary

**ALBERTA NORTH CHAPTER**
Jaymi Rumsey, President
Vanessa Pagtakhan, Vice-President
Mike Harding, Secretary
Bonnie Harrison, Treasurer
Sheldon Wong, Social Media Director

**ALBERTA SOUTH CHAPTER**
Tammy Patel, President
Rachel Ramsay, Vice-President
Jennifer Anderson, Past President
Michael Strocel, Treasurer
Sarah Quinn, Industry Liaison
Marwa Al-Alawi, Social Media Coordinator
Gurpreet Sidhu, Student Representative & Social Media Coordinator

**SAKSKATEWAN CHAPTER**
Joyce Allan, President
Shauna Houshmand, Vice-President / Past President
Meighan Kozlovski, Treasurer
Patricia Yuzik, Secretary

**MANITOBA CHAPTER**
Jodi Hyman, President
Michelle Rosentreter, Vice-President
Kathy Ramesar, Treasurer
Zoe Ignacio, Secretary, Scholarship’s Chair
Jordana Jones, Editor & Publisher of the Oncologic

**ONTARIO—HORSESHOE CHAPTER**
Heidi Thomas, President
Cheryl Page, Vice-President
Janny Proba, Secretary
Leslie Maskell, Treasurer

**ONTARIO—GREATER TORONTO CHAPTER**
Shawne Gray, President
Philiz Goh, Past President
Gayatre Maharaj, Director of Communications
Suzanne Scotland, Director of Recruiting and Retention
Sonali Kirshenbaum, Newsletter Editor In Chief
Kassie Nguyen, Events Coordinator
Taaha Ijaz, Student Representative

**ONTARIO—CHAMPLAIN CHAPTER**
Janelle Desjardins, President
Amber Killam, Vice-President
Vicky Samuel, Treasurer
Sara Olivier, Secretary

**ONTARIO—GREATER TORONTO CHAPTER**
Carolyn DeVito, President
Jenna McDougall, Vice-President
Laura Booth, Treasurer
Andrea Rose, Secretary

**PEI CHAPTER**
Lisa Bishop, President
Kara McQuid-Duffy, Past President
Janet Sharpe, Secretary

**NOVA SCOTIA CHAPTER**
Kara Jamieson, President
Heather Brander, Vice President
Jeannie Kennedy, Treasurer
Margaret Woods, Secretary

**NEWFOUNDLAND CHAPTER**
Bernadine O’Leary, Chapter Contact

**QUEBEC CHAPTER**
Maryse Carignan, Présidente
Marika Swidzinski, Conseillère - Liaison CANO/ACIO
Linda Hershon, Vice-Présidente
Alexi Parent, Trésorière
Billy Vinette, Secrétaire
Marie-Eve Belanger, Éducation et Communications
Annie Jean, Site web, Facebook et Communications
Maude Hebert, Prix d'Excellence
Gabrielle Chartier, Billy Vinette, Séminaire Annuel
Audrey Chouinard, Liaison formation universitaire
Amelie Paquet, Consultant
Christine Maheu, Consultant, Recherche

**NEW BRUNSWICK—MONCTON CHAPTER**
Carolyn DeVito, President
Jenna McDougall, Vice-President
Laura Booth, Treasurer
Andrea Rose, Secretary

**CANO ACIO**
Canadian Association of Nurses in Oncology
Association canadienne des infirmières en oncologie

ONLINE | OCTOBER 21–24, 2021
A LEAP IN CANCER CARE.  
A LEAP IN IMPACT.

Together with Siemens Healthineers, we are accelerating the fight against cancer and increasing the impact on healthcare. By combining our mission-critical technologies, software and services, we are harnessing the power of intelligent cancer care to shape the future of oncology.

With unmatched reach in the oncology space, we can provide a fully integrated, connected care pathway that addresses the entire patient journey from diagnosis to therapy to survivorship.

60% of women who benefit from Look Good Feel Better® are referred by their oncology nurse. Thank you for referring your patients. Together, we can help women facing cancer feel like themselves again.

60% des femmes qui bénéficient de Belle et bien dans sa peauMD en ont entendu parlé par leur équipe en oncologie. Merci de nous recommander à vos patientes. Ensemble, nous aidons les femmes atteintes de cancer à se sentir de nouveau elles-mêmes.
Continuing Nursing Education (CNE)

This event is approved for a maximum of 15.75 hours of accredited continuing nursing education by the Continuing Nursing Education (CNE) Office, Ingram School of Nursing, McGill University.

Cet événement est approuvé pour un maximum de 15.75 heures de formation continue accréditées par le Bureau de la formation continue en sciences infirmières (FCSI) de l’École des sciences infirmières Ingram de l’Université McGill.

Play the Virtual Scavenger Hunt!

There are many ways to earn points including:

- Explore the Exhibit Hall and engage with our sponsors!
- Attend as many sessions as possible!
- Earn additional points by attending Sponsored Symposia, Annual General Meeting, Award Ceremony, Keynote and Lectureship Sessions.
- Visit the Poster Hall for more codes.
- Find codes in announcements throughout the virtual conference.

For sessions, points are automatically applied to your total, if you complete the pop-up survey towards the end of each session. You MUST complete the survey to be awarded the points. The pop-up survey will appear near the end of each session.

**TOP 10 POINT EARNERS RECEIVE INCREDIBLE PRIZES FROM LOOK GOOD FEEL BETTER**

#1-3 Place: Beauty Haul Bag with an Array of Cosmetics (valued at $400+)
#4-10 Places: Mini-Cosmetic Gift Set

**SCAVENGER HUNT ENDS: SUNDAY, OCTOBER 24TH AT 2:00 PM EST**

Winners will be announced at the Closing Remarks.
Helping you Keep Healthcare Workers Safe from Hazardous Drug Exposure

Connect With Us at CANO/ACIO 2021 Virtual Conference
October 21 - October 24, 2021

Learn how we can help you keep clinicians safe from hazardous drug exposure and comply with USP <800> by keeping a closed system from beginning to end.

Scan the QR Code to learn more or visit: http://www.icumed.com/closedandcompliant

---

Apobiologix and IMD Health have partnered to provide a digital health platform, custom-tailored to the needs of Canadian Oncology Clinics

Learn more about the IMD Health Education Platform sponsored by Apobiologix by attending the product theatre session

Saturday, October 23, 2021
3:30 - 4:00pm EST

Visit the Apobiologix virtual booth to speak to a representative to learn how to get your institution involved.
Patient Support Program is here for your OGIVRI® & FULPHILA® patients

To learn more, please visit Viatris.ca

OGIVRI is a registered trademark of Mylan Institutional Inc., used under permission by BGP Pharma ULC, a Viatris company.
FULPHILA is a registered trademark of Mylan Institutional Inc., used under permission by BGP Pharma ULC, a Viatris company.
Viatris Advocate™ is a trademark of Mylan Inc., used under permission by BGP Pharma ULC, a Viatris company.
VIATRIS and VIATRIS & Design are trademarks of Mylan Inc., used under permission by BGP Pharma ULC, a Viatris company.
©2021 Viatris Inc. All rights reserved.
MUL-2021-2222E – SE2021

Verzenio®
abemaciclib

Verzenio is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates.
© 2020, Eli Lilly and Company. All rights reserved.

Lilly

PP-AL-CA-0026 (V 3.0)
# CANO/ACIO 2021 Program

## CONFERENCE DAY 1: Thursday, October 21, 2021

*All times listed in Eastern Standard Time (EST)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00AM – 11:45AM</td>
<td><strong>JAZZ PHARMACEUTICALS SPONSORED SYMPOSIUM</strong>&lt;br&gt;<strong>Patient Safety Framework: New Treatment Approaches for Small Cell Lung Cancer (SCLC) Patients</strong></td>
<td>Massey Nematollahi</td>
</tr>
<tr>
<td>11:00AM – 11:45AM</td>
<td><strong>TEVA CANADA SPONSORED SYMPOSIUM</strong>&lt;br&gt;<strong>Optimizing Delivery of Care in a Virtual Environment</strong></td>
<td>Kim Chapman, Philiz Goh &amp; Tristin Hamilton</td>
</tr>
<tr>
<td>11:30AM – 12:00PM</td>
<td><strong>POSTER PRESENTATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>11:45AM – 12:00PM</td>
<td><strong>OPENING REMARKS</strong>&lt;br&gt;Reanne Booker, Marie Marques &amp; Marilee Nowgesic</td>
<td></td>
</tr>
<tr>
<td>12:00PM – 1:40PM</td>
<td><strong>TRANSITIONS IN CARE</strong>&lt;br&gt;<strong>WORKSHOP (FIRST-COME, FIRST-SERVED. CAPACITY LIMITED TO 25)</strong>&lt;br&gt;<strong>Ensuring Safe and Efficient Patient Transitions from Cancer Care to Primary Care after Treatment: An Interactive Workshop focused on Nursing Practice</strong></td>
<td>Linda Watson</td>
</tr>
<tr>
<td>12:00PM – 12:20PM</td>
<td><strong>12:00PM – 12:20PM</strong>&lt;br&gt;<strong>Facilitating Transitions in Care: Best Practice Recommendations for Implementing Survivorship Care Plans</strong></td>
<td>Brittany Mutsaers</td>
</tr>
<tr>
<td>12:20PM – 1:00PM</td>
<td><strong>12:20PM – 1:00PM</strong>&lt;br&gt;<strong>Healing from the Inside Out—An Introduction to Cancer Coach Nursing in the Community Setting</strong></td>
<td>Hope Gillis</td>
</tr>
<tr>
<td>1:00PM – 1:20PM</td>
<td><strong>1:00PM – 1:20PM</strong>&lt;br&gt;<strong>Supporting Cancer Survivors Beyond Their Treatment</strong></td>
<td>Jessica Kitchen</td>
</tr>
<tr>
<td>1:20PM – 1:40PM</td>
<td><strong>1:20PM – 1:40PM</strong>&lt;br&gt;<strong>Implications of Patient- and Caregiver-Reported Outcomes Data on Nursing-Led Models of Cancer Care</strong></td>
<td>Jennifer Mayer</td>
</tr>
<tr>
<td>1:40pm – 3:00PM</td>
<td><strong>ADVOCACY</strong>&lt;br&gt;<strong>WORKSHOP (FIRST-COME, FIRST-SERVED. CAPACITY LIMITED TO 25)</strong>&lt;br&gt;<strong>Harnessing the Power of Patient-Reported Outcomes in Nursing Practice – From Individual Patients to System Transformation</strong></td>
<td>Linda Watson</td>
</tr>
<tr>
<td>1:40pm – 2:00pm</td>
<td><strong>1:40pm – 2:00pm</strong>&lt;br&gt;<strong>A Call to Action: Responding to Symptom Distress Virtually</strong></td>
<td>Tamara Homeward &amp; Dawn Knight</td>
</tr>
<tr>
<td>2:00pm – 2:40pm</td>
<td><strong>2:00pm – 2:40pm</strong>&lt;br&gt;<strong>Implementation of a Harmonizing Tool in a Dissonant Context: the Challenges and Revelations</strong></td>
<td>Renata Benc</td>
</tr>
<tr>
<td>2:40pm – 3:00pm</td>
<td><strong>2:40pm – 3:00pm</strong>&lt;br&gt;<strong>Implementing a Proactive Telephone Call for New Ambulatory Oncology Patients During the COVID-19 Pandemic</strong></td>
<td>Lauren Cosolo</td>
</tr>
<tr>
<td>3:00PM – 3:30PM</td>
<td><strong>POSTER PRESENTATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>3:30PM – 5:00PM</td>
<td><strong>RESOURCES (CONCURRENT)</strong>&lt;br&gt;<strong>WORKSHOP (FIRST-COME, FIRST-SERVED. CAPACITY LIMITED TO 25)</strong>&lt;br&gt;<strong>Putting Tools in Our Toolbox: Developing an Information Resource for Oncology Nurses Caring for Older Adults with Cancer</strong></td>
<td>Allison Wiens &amp; Fay Strolschein</td>
</tr>
<tr>
<td>3:30PM – 5:00PM</td>
<td><strong>3:30PM – 3:50PM</strong>&lt;br&gt;<strong>Leveraging Technology to Activate Patient Engagement and Improve Covid-19 Pre-screening Efficiency: A Qualitative Evaluation</strong></td>
<td>Carre MacDonald-Liska &amp; Lynne Jolicoeur</td>
</tr>
<tr>
<td>3:30PM – 5:00PM</td>
<td><strong>3:50PM – 4:10PM</strong>&lt;br&gt;<strong>Providing Virtual Nursing Systemic Therapy Patient Education: A Qualitative Evaluation</strong></td>
<td>Penny Hanniford &amp; Julie Leclair</td>
</tr>
<tr>
<td>3:30PM – 5:00PM</td>
<td><strong>BOARD SPONSORED WORKSHOP (FIRST-COME, FIRST-SERVED. CAPACITY LIMITED TO 25)</strong>&lt;br&gt;<strong>Roundtable Workshop – Moving Research Forward During COVID-19</strong></td>
<td>Christine Maheu, Manon Lemonde &amp; Samantha Mayo</td>
</tr>
<tr>
<td>3:30PM – 5:00PM</td>
<td><strong>4:10PM – 4:30PM</strong>&lt;br&gt;<strong>Improving Outcomes for Adolescents and Young Adults with Cancer: Driving Change using a National Framework and Provincial Data</strong></td>
<td>Sarah Thompson</td>
</tr>
<tr>
<td>3:30PM – 5:00PM</td>
<td><strong>4:30PM – 5:10PM</strong>&lt;br&gt;<strong>The Processes and Experiences of Oncology Healthcare Providers Managing Acute Cancer Symptoms Within Canadian Urgent Cancer Clinics</strong></td>
<td>Tammy Patel</td>
</tr>
<tr>
<td>5:00PM – 5:20PM</td>
<td><strong>5:00PM – 5:20PM</strong>&lt;br&gt;<strong>Inuusinni Aqquasaqtaq: Using E-Learning Modules to Engage Inuit Patients and Healthcare Providers</strong></td>
<td>Reyna Uriarte</td>
</tr>
<tr>
<td>5:00PM – 5:20PM</td>
<td><strong>5:10PM – 5:30PM</strong>&lt;br&gt;<strong>Hematology Oncology Triage RN: A call to action through the COVID-19 pandemic</strong></td>
<td>Angela Blasutti-Boisvert</td>
</tr>
<tr>
<td>CONFERENCE PROGRAM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CONFERENCE DAY 1: Thursday, October 21, 2021

All times listed in Eastern Standard Time (EST)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:45PM – 6:45PM</td>
<td>GSK FOCUS GROUP (BY INVITATION ONLY)</td>
</tr>
<tr>
<td>5:45PM – 6:45PM</td>
<td>SAVE YOUR SKIN FOUNDATION FOCUS GROUP (BY INVITATION ONLY)</td>
</tr>
</tbody>
</table>

### CONFERENCE DAY 2: Friday, October 22, 2021

All times listed in Eastern Standard Time (EST)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00AM – 11:45AM</td>
<td>JANSSEN SPONSORED SYMPOSIUM: Enhancing the Patient Experience in Multiple Myeloma: Optimizing the Administration of Novel Agents (Michelle Foreman &amp; Kari Kolm)</td>
</tr>
<tr>
<td>11:00AM – 11:45AM</td>
<td>JAZZ PHARMACEUTICALS SPONSORED SYMPOSIUM: Advances in AML Treatment: Introducing VYXEOS® (Cindy Murray)</td>
</tr>
<tr>
<td>12:00PM – 1:00PM</td>
<td>CANO AWARDS OF EXCELLENCE CEREMONY</td>
</tr>
<tr>
<td>1:00PM – 2:30PM</td>
<td>WORKSHOP (FIRST-COME, FIRST-SERVED. CAPACITY LIMITED TO 25): Transforming Health and Wellness Through Musical Improvisation (Laurie Sadowski)</td>
</tr>
<tr>
<td>1:00PM – 2:30PM</td>
<td>BOARD SPONSORED WORKSHOP (FIRST-COME, FIRST-SERVED. CAPACITY LIMITED TO 25): Virtual Cancer Care: Practice Standards for the Specialized Oncology Nurse (Samantha Scime, Margaret Fitch, Simonne Simon &amp; Charlotte Lee)</td>
</tr>
<tr>
<td>1:00PM – 2:30PM</td>
<td>Moving the COSTaRS Practice Guides into Action: Over 10 Years of Research on Implementing in Clinical practice (Dawn Stacey)</td>
</tr>
<tr>
<td>2:30PM – 3:00PM</td>
<td>POSTER PRESENTATIONS</td>
</tr>
<tr>
<td>3:00PM – 4:00PM</td>
<td>CANO/CCS JOINT SYMPOSIUM: Equity in virtual care: ensuring underserved populations aren't left behind (Reanne Booker, Tracy Torchetti, Laura Burnett)</td>
</tr>
<tr>
<td><strong>CULTURALLY SAFE CARE (CONCURRENT)</strong></td>
<td><strong>CLINICAL PRACTICE (CONCURRENT)</strong></td>
</tr>
<tr>
<td>4:00PM – 4:20PM</td>
<td>Understanding Culturally Safe Cancer Survivorship Care with Inuit in an Urban Community (Wendy Gifford)</td>
</tr>
<tr>
<td>4:20PM – 4:40PM</td>
<td>Exploring Culturally Safe Cancer Survivorship Care with Pikwàkanàgam First Nation (Wendy Gifford)</td>
</tr>
<tr>
<td>4:40PM – 5:00PM</td>
<td>Implementation of Subcutaneous Trastuzumab in Nunavut: An Inter-Jurisdictional Collaboration (Jennifer Newton)</td>
</tr>
<tr>
<td>5:15PM – 6:45PM</td>
<td>PFIZER CANADA FOCUS GROUP (By Invitation Only)</td>
</tr>
</tbody>
</table>

### CONFERENCE DAY 3: Saturday, October 23, 2021

All times listed in Eastern Standard Time (EST)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00AM – 5:00PM</td>
<td>Exhibit Hall &amp; Networking</td>
</tr>
<tr>
<td>9:00AM – 9:45AM</td>
<td>CANO/ACIO ANNUAL GENERAL MEETING</td>
</tr>
<tr>
<td><strong>LEADERSHIP (CONCURRENT)</strong></td>
<td><strong>EDUCATION (CONCURRENT)</strong></td>
</tr>
<tr>
<td>10:00AM – 10:20AM</td>
<td>How Creativity and Innovation Can Support Fiscal Responsibility and Excellence in Patient Care (Colleen Graham)</td>
</tr>
<tr>
<td>10:20AM – 10:40AM</td>
<td>Building Capacity to Leverage Nursing and Allied Health Research Perspectives Across a Provincial Cancer Program (Andrea Knox)</td>
</tr>
</tbody>
</table>
## CONFERENCE DAY 3: Saturday, October 23, 2021

All times listed in Eastern Standard Time (EST)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40AM – 11:00AM</td>
<td>The Integration of Telehealth in the Oncology Nurse Navigators (ONN) Practice: Challenges and Opportunities</td>
<td>Josee Beaudet</td>
</tr>
<tr>
<td>10:40AM – 11:00AM</td>
<td>Nurse Practitioner Fellowship Program in Complex Malignant Hematology</td>
<td>Margaret Forbes</td>
</tr>
<tr>
<td>11:00AM – 11:30AM</td>
<td>Break</td>
<td>Exhibit Hall &amp; Networking</td>
</tr>
<tr>
<td>11:00AM – 11:30AM</td>
<td>PRODUCT THEATRE PRESENTATION FEATURING PFIZER CANADA</td>
<td></td>
</tr>
<tr>
<td>11:30AM – 11:50AM</td>
<td>The Great Communication Link: Reconciliation of Two Electronic Systems for Accessibility of Nursing Documentation Between Cancer Care Teams</td>
<td>Kathy Carothers</td>
</tr>
<tr>
<td>11:30AM – 11:50AM</td>
<td>INFORMATICS IN ONCOLOGY (CONCURRENT)</td>
<td></td>
</tr>
<tr>
<td>11:30AM – 11:50AM</td>
<td>VIRTUAL NAVIGATION (CONCURRENT)</td>
<td></td>
</tr>
<tr>
<td>11:50AM – 12:10PM</td>
<td>Implementation of an App-Based Nursing Education Initiative</td>
<td>Devon Pikington</td>
</tr>
<tr>
<td>11:50AM – 12:10PM</td>
<td>PRODUCT THEATRE PRESENTATION FEATURING PFIZER CANADA</td>
<td></td>
</tr>
<tr>
<td>11:50AM – 12:30PM</td>
<td>Oncology Lung SMArTVIEW</td>
<td>Jennifer Loursbury</td>
</tr>
<tr>
<td>12:45PM – 1:30PM</td>
<td>Break</td>
<td>Exhibit Hall &amp; Networking</td>
</tr>
<tr>
<td>12:45PM – 1:30PM</td>
<td>ASTELLAS SPONSORED SYMPOSIUM Multidisciplinary Management of Cancer-Related Fatigue</td>
<td>Dr. Dorothy Lo</td>
</tr>
<tr>
<td>12:45PM – 1:30PM</td>
<td>ASTRAZENECA AND MERCK CANADA SPONSORED SYMPOSIUM Real-World Management of Patients on PARPi Across Tumor Types: Practical Considerations for Clinical Practice</td>
<td></td>
</tr>
<tr>
<td>1:45PM – 2:30PM</td>
<td>KEYNOTE ADDRESS Opening Up Eyes, Hearts and Minds</td>
<td>Talli Osborne</td>
</tr>
<tr>
<td>2:30PM – 2:50PM</td>
<td>Exploring the Post-Test Psychological Functioning of Women Undergoing Multi-Gene Testing for Hereditary Breast and Ovarian Cancer Risk</td>
<td>Lindsay Carlsson</td>
</tr>
<tr>
<td>2:30PM – 2:50PM</td>
<td>CLINICAL PRACTICE (CONCURRENT) EXPLORING THE POST-TEST PSYCHOLOGICAL FUNCTIONING OF WOMEN UNDERGOING MULTI-GENE TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER RISK</td>
<td></td>
</tr>
<tr>
<td>2:50 PM – 3:10PM</td>
<td>The Use of Hyperbaric Oxygen Therapy to Treat Infection in AML</td>
<td>Kan Kolm</td>
</tr>
<tr>
<td>2:50 PM – 3:10PM</td>
<td>PANDEMIC ADAPTATION (CONCURRENT) Responding to a Pandemic: Point Prevalence COVID Testing in Asymptomatic Chemotherapy Patients</td>
<td>Kirsty Weil &amp; Angela Boudreau</td>
</tr>
<tr>
<td>3:10PM – 3:30PM</td>
<td>A Palliative Care Approach to the Management of Malignant Bowel Obstruction: What Nurses Need to Know</td>
<td>Susan McClennen</td>
</tr>
<tr>
<td>3:10PM – 3:30PM</td>
<td>Responding to the Pandemic: Development and Implementation of a Secondary COVID–19 Assessment Clinic for Ambulatory Patients with Cancer</td>
<td>Kathy Carothers</td>
</tr>
<tr>
<td>3:30PM – 4:00PM</td>
<td>Break</td>
<td>Exhibit Hall &amp; Networking</td>
</tr>
<tr>
<td>3:30PM – 4:00PM</td>
<td>PRODUCT THEATRE PRESENTATION FEATURING APOBIOLOGIX &amp; HANSAMED</td>
<td></td>
</tr>
<tr>
<td>4:00PM – 4:20PM</td>
<td>Preoperative Patient Education via Animated Videos in Head and Neck Surgery: A Randomized Controlled Trial</td>
<td>Gabrielle Chartier</td>
</tr>
<tr>
<td>4:00PM – 4:20PM</td>
<td>NURSES LEADING THE WAY The Multi-Disciplinary Approach to Preventing Cutaneous Toxicity in Patients Receiving Oncology Treatments</td>
<td>Nour Dayeh</td>
</tr>
</tbody>
</table>
### CONFERENCE DAY 3: Saturday, October 23, 2021

All times listed in Eastern Standard Time (EST)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30PM – 5:30PM</td>
<td>CANO/CAPO JOINT SYMPOSIUM Patient Advocates Joining Forces to Advance Patient Advocacy in Cancer Care</td>
<td>Carmen G. Loiselle, Reanne Booker, Fiana Ross, Samar Attieh, Karine Lepage &amp; Eva Villalba</td>
</tr>
</tbody>
</table>

### CONFERENCE DAY 4: Sunday, October 24, 2021

All times listed in Eastern Standard Time (EST)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00AM – 3:30PM</td>
<td>Exhibit Hall &amp; Networking</td>
<td></td>
</tr>
<tr>
<td>10:00AM – 12:00PM</td>
<td>WORKSHOP (FIRST-COME, FIRST-SERVED. CAPACITY LIMITED TO 25) Wishing, Worrying, Wondering: Palliative Care Communication for Oncology Nursing</td>
<td>Janet Vandale</td>
</tr>
<tr>
<td>10:00AM – 10:20AM</td>
<td>MODEL OF CARE A Journey in Transformation—Innovating the Model of Care (MOC)</td>
<td>Suganya Vadivelu</td>
</tr>
<tr>
<td>10:20AM – 10:40AM</td>
<td>MODEL OF CARE Oncology Patient Characteristics Tool</td>
<td>Jennifer Lounsbury</td>
</tr>
<tr>
<td>10:40AM – 11:00AM</td>
<td>MODEL OF CARE Outpatient CAR-T Therapy Utilizing a Nurse Practitioner-Led Model of Care</td>
<td>Margaret Forbes</td>
</tr>
<tr>
<td>11:00AM – 11:20AM</td>
<td>GERIATRIC ONCOLOGY Exploring the Ethical Dimensions of Oncology Nurses’ Practice When Caring for Older Adults with Cancer in British Columbia</td>
<td>Lorelei Newton</td>
</tr>
<tr>
<td>11:20AM – 11:40AM</td>
<td>GERIATRIC ONCOLOGY Experiences of Older Adult Cancer Survivors Across the COVID-19 Pandemic: A Longitudinal Qualitative Study</td>
<td>Heather Kilgour</td>
</tr>
<tr>
<td>11:40AM – 12:00PM</td>
<td>GERIATRIC ONCOLOGY Understanding Gaps in Care of Older Albertans with Cancer: Age-Analysis of Patient-Reported Outcome and Experience Measures</td>
<td>Fay Strohschein</td>
</tr>
<tr>
<td>12:00 PM – 12:45PM</td>
<td>HELENE HUDSON LECTURE &amp; AWARD PRESENTATION SPONSORED BY AMGEN / CONFÉRENCE HELENE HUDSON ET REMISE DE PRIX SPONSORISÉE PAR AMGEN It’s a Broken System: Inequities in Access to Oncology Care Among Indigenous Peoples in Canada</td>
<td>Tara Horrill</td>
</tr>
<tr>
<td>1:00PM – 1:45PM</td>
<td>Break</td>
<td>Exhibit Hall &amp; Networking</td>
</tr>
<tr>
<td>1:00PM – 1:45PM</td>
<td>ASTRazeneca CANADA SPONSORED SYMPOSIUM The Essential Role of Breast Care Nurses in the Management of Treatment Related Adverse Events</td>
<td>Cindy Railton &amp; Allie Hershey</td>
</tr>
<tr>
<td>1:00PM – 1:45PM</td>
<td>JANSSEN SPONSORED SYMPOSIUM Optimizing Care for Patients with CLL</td>
<td>Dr. Matthew Kang</td>
</tr>
<tr>
<td>2:00PM – 2:45PM</td>
<td>CLINICAL LECTURESHIP AND AWARD PRESENTATION SPONSORED BY MERCK / CONFÉRENCE CLINIQUE ET REMISE DE PRIX SPONSORISÉE PAR MERCK Canadian Nursing and Genomics: An Engagement Initiative</td>
<td>Lindsay Carlsson &amp; Jacqueline Limoges</td>
</tr>
<tr>
<td>2:50PM – 3:30PM</td>
<td>LET’S TALK ABOUT IT “You get used to a certain kind of horrible” — Moral Distress in Oncology Nursing</td>
<td>Brenda Peters-Waltral</td>
</tr>
<tr>
<td>2:50PM – 3:30PM</td>
<td>LET’S TALK ABOUT IT L’intégration de la télésanté dans la pratique des infirmières pivots en oncologie (IPO) : défis et opportunités</td>
<td>Josée Beaudet, Sabrina Lapointe, Yoséline Lensens, Amela Kovac &amp; Sarah Grenier Darveau</td>
</tr>
<tr>
<td>3:30PM – 3:40PM</td>
<td>CLOSING REMARKS</td>
<td>Reanne Booker</td>
</tr>
</tbody>
</table>
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, cardiovascular disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.ca
DEVELOPMENT OF A NATIONAL STANDARD FOR PALLIATIVE CARE IN CANADA

This framework aims to inform national standards by setting the competencies for palliative care practice. Currently applied to five disciplines, this framework can be expanded to other disciplines and populations.

It serves as a guiding document for jurisdictions that lack an explicit set of palliative care competencies, and also as high-level guidance for provinces that have built their own competency frameworks.

Specifically, the disciplines with competencies in the framework:

- Nurses
- General Physicians
- Social Workers
- Personal Support Workers
- Volunteers

Access the framework and complementary resources at www.partnershipagainstcancer.ca/palliative-care-competency-framework
# Abstract Posters

<table>
<thead>
<tr>
<th>ABSTRACT NUMBER</th>
<th>ABSTRACT TITLE</th>
<th>PRESENTERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-01</td>
<td>Creating Connections: How Comfort Talk Can be Used by Nurses to Improve Symptom</td>
<td>Caroline Arbour</td>
</tr>
<tr>
<td></td>
<td>Management During Outpatient Chemotherapy</td>
<td></td>
</tr>
<tr>
<td>P-02</td>
<td>Leveraging Role Alignment and Dissonance Cues in Caregiver-Reported Outcomes</td>
<td>Scott Beck</td>
</tr>
<tr>
<td></td>
<td>Work: A Study of Colorectal Cancer Patients and Caregivers</td>
<td></td>
</tr>
<tr>
<td>P-03</td>
<td>Using Smart Pump Technology to Enhance Patient Care Through Safe</td>
<td>Angela Boudreau</td>
</tr>
<tr>
<td></td>
<td>Administration of Medication</td>
<td></td>
</tr>
<tr>
<td>P-04</td>
<td>Responding to Need in a Crisis for the Safety of All During a Pandemic</td>
<td>Angela Boudreau</td>
</tr>
<tr>
<td>P-05</td>
<td>Evaluating Patient Assignments with a New Mixed Nursing Model on a Hematology</td>
<td>Theresa Charters</td>
</tr>
<tr>
<td></td>
<td>Oncology Unit</td>
<td></td>
</tr>
<tr>
<td>P-06</td>
<td>Game off, Game On: Let’s Take a Timeout for Safety</td>
<td>Stephanie Clermont</td>
</tr>
<tr>
<td>P-07</td>
<td>A Call to Action: Development of a Chemotherapy/Biotherapy Certification</td>
<td>Lauren Cosolo</td>
</tr>
<tr>
<td></td>
<td>Program</td>
<td></td>
</tr>
<tr>
<td>P-08</td>
<td>Enhancing Interdisciplinary Palliative Care Competency Across the Country: The</td>
<td>Kristen DeCaria</td>
</tr>
<tr>
<td></td>
<td>Role of Nurses in the Palliative Care Approach</td>
<td></td>
</tr>
<tr>
<td>P-09</td>
<td>O-Prep Learning Pathways: Support for Oncology Nurses to Achieve and Maintain</td>
<td>Sydney Farkas</td>
</tr>
<tr>
<td></td>
<td>Specialized Knowledge and Skills</td>
<td></td>
</tr>
<tr>
<td>P-10</td>
<td>Oncology Education for All: Success in Meeting an Organizational Learning Need</td>
<td>Sydney Farkas</td>
</tr>
<tr>
<td>P-11</td>
<td>Implementing Culturally Safe Cancer Survivorship Supports in Inuit Nunangat:</td>
<td>Wendy Gifford</td>
</tr>
<tr>
<td></td>
<td>A Study Protocol</td>
<td></td>
</tr>
<tr>
<td>P-12</td>
<td>Improving Cancer Survivorship Among Indigenous Peoples: A Systematic Review and</td>
<td>Wendy Gifford</td>
</tr>
<tr>
<td></td>
<td>Narrative Synthesis of the Literature</td>
<td></td>
</tr>
<tr>
<td>P-13</td>
<td>Clinician Burnout—A Local Response to a Systemic Concern</td>
<td>Colleen Graham</td>
</tr>
<tr>
<td>P-14</td>
<td>Examining Psychological Stress in Adolescents and Young Adults Cancer Patients</td>
<td>Claudia Grande</td>
</tr>
<tr>
<td></td>
<td>as the Link to Higher Levels of Mental Health and Disease Progression</td>
<td></td>
</tr>
<tr>
<td>P-15</td>
<td>A Call to Action: Bringing Patients and the Health Care Team Together to Create</td>
<td>Shawne Gray</td>
</tr>
<tr>
<td></td>
<td>an HPV Education Resource</td>
<td></td>
</tr>
<tr>
<td>P-16</td>
<td>Communauté de Pratique Virtuelle des Infirmières Pivot en Oncologie au Québec</td>
<td>Josée Beaudet</td>
</tr>
<tr>
<td>P-17</td>
<td>Integration of an Innovative Complementary Approach Inspired by Clinical</td>
<td>Danny Hjeij</td>
</tr>
<tr>
<td></td>
<td>Hypnosis into Oncology Care: Nurses’ Perception of Comfort Talk</td>
<td></td>
</tr>
<tr>
<td>P-19</td>
<td>Implementing Teleconference Multidisciplinary Rounds on a Hematology/ Stem</td>
<td>Carolyn Kelly-Ruetz</td>
</tr>
<tr>
<td></td>
<td>Cell Transplant Floor (C4)</td>
<td></td>
</tr>
<tr>
<td>P-20</td>
<td>Patient Needs and Resource Intensity Weighting in the Ambulatory Care Unit</td>
<td>Andrea Knox</td>
</tr>
<tr>
<td>P-21</td>
<td>Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient</td>
<td>Lucy Gilbert</td>
</tr>
<tr>
<td></td>
<td>(MMRp) Endometrial Cancer Cohorts from the GARNET Study</td>
<td></td>
</tr>
<tr>
<td>P-22</td>
<td>Validating VoxNeuro Cognitive Health Assessments as an Objective Measure of</td>
<td>Marian Luctkar-Flude</td>
</tr>
<tr>
<td></td>
<td>Cognitive Function in Cancer Survivorship Research</td>
<td></td>
</tr>
<tr>
<td>P-23</td>
<td>Oncology Nurses Self-Management Support Interventions: Should There Be Greater</td>
<td>Carrie MacDonald-Liska</td>
</tr>
<tr>
<td></td>
<td>Opportunity for Health Coaching? An Integrative Literature Review</td>
<td></td>
</tr>
<tr>
<td>P-24</td>
<td>Needs Assessment Survey to Identify Content Priority Area for a Primary Care</td>
<td>Christine Maheu</td>
</tr>
<tr>
<td></td>
<td>Provider E-Course on Supporting Cancer Survivors with Return to Work</td>
<td></td>
</tr>
<tr>
<td>ABSTRACT NUMBER</td>
<td>ABSTRACT TITLE</td>
<td>PRESENTERS</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>P-25</td>
<td>Optimization of Oncology Program—Providing Convenient Extraordinary Care to Oncology Patient Population</td>
<td>Amina Malik</td>
</tr>
<tr>
<td>P-26</td>
<td>Psychosocial Needs of Adults with Advanced Multiple Myeloma: Findings from a Qualitative Study</td>
<td>Samantha Mayo</td>
</tr>
<tr>
<td>P-27</td>
<td>Cancer-Related Cognitive Impairment: Evidence-Based Strategies for Supporting our Patients</td>
<td>Samantha Mayo</td>
</tr>
<tr>
<td>P-28</td>
<td>Patient-Reported Outcomes (PROs) in Patients with Advanced or Recurrent dMMR/MSI-H Endometrial Cancer (EC) Receiving Dostarlimab</td>
<td>Laurie Eliason</td>
</tr>
<tr>
<td>P-29</td>
<td>Breast Cancer in Pregnancy: Creating Multidisciplinary Modules for Oncology Nurses</td>
<td>Linda Muraca</td>
</tr>
<tr>
<td>P-30</td>
<td>The Good, The Bad and The Ugly of Managing Mucositis in Hematopoietic Stem Cell Transplant Patients.</td>
<td>Phillip Nguyen</td>
</tr>
<tr>
<td>P-31</td>
<td>Therapeutic Touch Amid COVID 19—The Forgotten Skill</td>
<td>Phillip Nguyen</td>
</tr>
<tr>
<td>P-32</td>
<td>Evaluating the Effectiveness of a Training Program to Support Nurses to Administer Cryopreserved Hematopoietic Stem Cells by Intravenous Push Method</td>
<td>Cheryl Page</td>
</tr>
<tr>
<td>P-33</td>
<td>The Importance of Peer Support for People Diagnosed with a Blood Cancer</td>
<td>Pascale Rousseau</td>
</tr>
<tr>
<td>P-34</td>
<td>Evaluating the Efficacy of Virtual Visits Versus In-Person Visits During COVID-19</td>
<td>Laurie Sadowski</td>
</tr>
<tr>
<td>P-35</td>
<td>The Development of a Symptom Diary for Cancer Patients Receiving Immunotherapy</td>
<td>Sonya Sangha</td>
</tr>
<tr>
<td>P-36</td>
<td>The Use of Chlorhexidine Wipes to Reduce Central Line Infections in Allogeneic Stem Cell Transplant patients</td>
<td>Samantha Scime</td>
</tr>
<tr>
<td>P-37</td>
<td>Breast Cancer Survivorship Care: A Simulation-Based Educational Intervention for Primary Care Providers</td>
<td>Amina Silva</td>
</tr>
<tr>
<td>P-38</td>
<td>Perspectives and Experiences of Informal Caregivers of Cancer Patients Undergoing Palliative Treatment: An Integrative Review</td>
<td>Amina Silva</td>
</tr>
<tr>
<td>P-39</td>
<td>Simulation-Based Education in Oncology Nursing: An Integrative Review</td>
<td>Amina Silva</td>
</tr>
<tr>
<td>P-41</td>
<td>When Cancer is Me: A Layered Interpretive Description of the Identity Experience of Adult Haematology Oncology Patients</td>
<td>Jennifer Stephens</td>
</tr>
<tr>
<td>P-42</td>
<td>Implementation Strategies to Support Evidence-InformedSymptom Management Among Outpatient Oncology Nurses: A Scoping Review</td>
<td>Kylie Feggart</td>
</tr>
<tr>
<td>P-43</td>
<td>What Should We Know About Cannabis Use in Oncology? Advice for Oncology nurses</td>
<td>Billy Vinette</td>
</tr>
<tr>
<td>P-44</td>
<td>Complex Malignant Hematology – A Standardized Online Curriculum to Support New Model of Care</td>
<td>Jiahui Wong</td>
</tr>
<tr>
<td>P-45</td>
<td>Building Competency-Based Education to Develop and Maintain Chemotherapy Administration Skills Among Nurses in a New Inpatient Medicine/Oncology Unit</td>
<td>Samantha Soto</td>
</tr>
</tbody>
</table>
Oral, weight-based dosing of LENVIMA® helps to optimize treatment in HCC.

The weight-based dosing of LENVIMA® allows tailoring of starting doses for all patients to balance optimal efficacy and tolerability.

SAFETY INFORMATION
LENVIMA® (lenvatinib) is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (HCC). Efficacy and safety data for Child-Pugh Class B and Class C are not available.

Consult the Product Monograph at https://ca.eisai.com/-/media/Files/CanadaEisai/LENVIMA-Product-Monograph-EN.pdf for important information about:
- The most serious warnings and precautions regarding hypertension and its complications, cardiac failure, arterial thromboembolism, gastrointestinal perforation/fistula formation, hepatotoxicity/hepatic failure, renal failure/impairment, hemorrhage, and posterior reversible encephalopathy syndrome (PRES)
- Other relevant warnings and precautions regarding prior anticancer treatments, osteonecrosis of the jaw, wound healing complications, QT interval prolongation, hypocalcemia, hypothyroidism/thyroid dysfunction, fatigue, diarrhea, proteinuria, fertility, pregnancy and breastfeeding, blood cell count monitoring and electrolyte-disrupting drugs
- Conditions of clinical use, adverse reactions, drug interactions, and dosing and administration

The Product Monograph is also available by calling Eisai Limited at 1-888-551-0547.

LENVIMA® is a registered trademark owned by Eisai R&D Management Co., Ltd. © 2021 Eisai Canada Limited. All rights reserved.

Oral capsules taken once daily

Weight-based dosing
<60 kg: 8 mg
≥60 kg: 12 mg

Swallow whole with water
Whole capsule can be dissolved in a tablespoon of water or apple juice!

Taken with or without food

Evidence-based strategies to enhance patient safety during the challenges of COVID care

Surefuser+: Elastomeric infusion system for chemotherapy and pain management, antibiotic therapy, and infusion-related therapies

SecurAcath: Reduces CLABSI, prevents catheter dislodgement for the Life of the Line. Improves efficiency with catheter care & maintenance, significantly reduces nursing time compared to adhesive securement devices

Punctur Guard: CT rated Positive pressure Huber needle, eliminates heparin flushing, and reduces TPA (alteplase) usage

StatSeal: Helps standardize, simplify & minimize post-procedure care and catheter maintenance. Promote rapid hemostasis (including on highly anticoagulated COVID patients) and prevent unnecessary dressing change

COMING SOON! IP Echo: Handheld ultrasound device, with built-in screen on the probe for ease of use and enhanced convenience.

Evidence-based strategies to optimize VAD outcomes with COVID patients

Surefuser+: Lightweight, closed system with built-in safety features.

SecurAcath

COMING SOON!

Oral capsules

Weight-based dosing

Swallow whole with water

Taken with or without food

Oral, weight-based dosing of LENVIMA® helps to optimize treatment in HCC.

SAFETY INFORMATION
LENVIMA® (lenvatinib) is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (HCC). Efficacy and safety data for Child-Pugh Class B and Class C are not available.

Consult the Product Monograph at https://ca.eisai.com/-/media/Files/CanadaEisai/LENVIMA-Product-Monograph-EN.pdf for important information about:
- The most serious warnings and precautions regarding hypertension and its complications, cardiac failure, arterial thromboembolism, gastrointestinal perforation/fistula formation, hepatotoxicity/hepatic failure, renal failure/impairment, hemorrhage, and posterior reversible encephalopathy syndrome (PRES)
- Other relevant warnings and precautions regarding prior anticancer treatments, osteonecrosis of the jaw, wound healing complications, QT interval prolongation, hypocalcemia, hypothyroidism/thyroid dysfunction, fatigue, diarrhea, proteinuria, fertility, pregnancy and breastfeeding, blood cell count monitoring and electrolyte-disrupting drugs
- Conditions of clinical use, adverse reactions, drug interactions, and dosing and administration

The Product Monograph is also available by calling Eisai Limited at 1-888-551-0547.

LENVIMA® is a registered trademark owned by Eisai R&D Management Co., Ltd. © 2021 Eisai Canada Limited. All rights reserved.

Oral capsules taken once daily

Weight-based dosing
<60 kg: 8 mg
≥60 kg: 12 mg

Swallow whole with water
Whole capsule can be dissolved in a tablespoon of water or apple juice!

Taken with or without food

Evidence-based strategies to enhance patient safety during the challenges of COVID care

Surefuser+: Elastomeric infusion system for chemotherapy and pain management, antibiotic therapy, and infusion-related therapies

SecurAcath: Reduces CLABSI, prevents catheter dislodgement for the Life of the Line. Improves efficiency with catheter care & maintenance, significantly reduces nursing time compared to adhesive securement devices

Punctur Guard: CT rated Positive pressure Huber needle, eliminates heparin flushing, and reduces TPA (alteplase) usage

StatSeal: Helps standardize, simplify & minimize post-procedure care and catheter maintenance. Promote rapid hemostasis (including on highly anticoagulated COVID patients) and prevent unnecessary dressing change

COMING SOON! IP Echo: Handheld ultrasound device, with built-in screen on the probe for ease of use and enhanced convenience.

Evidence-based strategies to optimize VAD outcomes with COVID patients

Surefuser+: Lightweight, closed system with built-in safety features.

SecurAcath

COMING SOON!

Oral capsules

Weight-based dosing

Swallow whole with water

Taken with or without food

Oral, weight-based dosing of LENVIMA® helps to optimize treatment in HCC.

SAFETY INFORMATION
LENVIMA® (lenvatinib) is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (HCC). Efficacy and safety data for Child-Pugh Class B and Class C are not available.

Consult the Product Monograph at https://ca.eisai.com/-/media/Files/CanadaEisai/LENVIMA-Product-Monograph-EN.pdf for important information about:
- The most serious warnings and precautions regarding hypertension and its complications, cardiac failure, arterial thromboembolism, gastrointestinal perforation/fistula formation, hepatotoxicity/hepatic failure, renal failure/impairment, hemorrhage, and posterior reversible encephalopathy syndrome (PRES)
- Other relevant warnings and precautions regarding prior anticancer treatments, osteonecrosis of the jaw, wound healing complications, QT interval prolongation, hypocalcemia, hypothyroidism/thyroid dysfunction, fatigue, diarrhea, proteinuria, fertility, pregnancy and breastfeeding, blood cell count monitoring and electrolyte-disrupting drugs
- Conditions of clinical use, adverse reactions, drug interactions, and dosing and administration

The Product Monograph is also available by calling Eisai Limited at 1-888-551-0547.

LENVIMA® is a registered trademark owned by Eisai R&D Management Co., Ltd. © 2021 Eisai Canada Limited. All rights reserved.

Oral capsules taken once daily

Weight-based dosing
<60 kg: 8 mg
≥60 kg: 12 mg

Swallow whole with water
Whole capsule can be dissolved in a tablespoon of water or apple juice!

Taken with or without food

Evidence-based strategies to enhance patient safety during the challenges of COVID care

Surefuser+: Elastomeric infusion system for chemotherapy and pain management, antibiotic therapy, and infusion-related therapies

SecurAcath: Reduces CLABSI, prevents catheter dislodgement for the Life of the Line. Improves efficiency with catheter care & maintenance, significantly reduces nursing time compared to adhesive securement devices

Punctur Guard: CT rated Positive pressure Huber needle, eliminates heparin flushing, and reduces TPA (alteplase) usage

StatSeal: Helps standardize, simplify & minimize post-procedure care and catheter maintenance. Promote rapid hemostasis (including on highly anticoagulated COVID patients) and prevent unnecessary dressing change

COMING SOON! IP Echo: Handheld ultrasound device, with built-in screen on the probe for ease of use and enhanced convenience.

Evidence-based strategies to optimize VAD outcomes with COVID patients

Surefuser+: Lightweight, closed system with built-in safety features.

SecurAcath

COMING SOON!

Oral capsules

Weight-based dosing

Swallow whole with water

Taken with or without food

Oral, weight-based dosing of LENVIMA® helps to optimize treatment in HCC.

SAFETY INFORMATION
LENVIMA® (lenvatinib) is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (HCC). Efficacy and safety data for Child-Pugh Class B and Class C are not available.

Consult the Product Monograph at https://ca.eisai.com/-/media/Files/CanadaEisai/LENVIMA-Product-Monograph-EN.pdf for important information about:
- The most serious warnings and precautions regarding hypertension and its complications, cardiac failure, arterial thromboembolism, gastrointestinal perforation/fistula formation, hepatotoxicity/hepatic failure, renal failure/impairment, hemorrhage, and posterior reversible encephalopathy syndrome (PRES)
- Other relevant warnings and precautions regarding prior anticancer treatments, osteonecrosis of the jaw, wound healing complications, QT interval prolongation, hypocalcemia, hypothyroidism/thyroid dysfunction, fatigue, diarrhea, proteinuria, fertility, pregnancy and breastfeeding, blood cell count monitoring and electrolyte-disrupting drugs
- Conditions of clinical use, adverse reactions, drug interactions, and dosing and administration

The Product Monograph is also available by calling Eisai Limited at 1-888-551-0547.

LENVIMA® is a registered trademark owned by Eisai R&D Management Co., Ltd. © 2021 Eisai Canada Limited. All rights reserved.
ARE YOUR PATIENTS SUFFERING FROM ONCOLOGY TREATMENTS?

SO IS THEIR SKIN.

Learn more about skin toxicities related to oncology treatments by visiting the La Roche-Posay virtual booth.
Akynzeo® Formulary Coverage

Speak with your Akynzeo® representative today to learn if public coverage is available in your province!

mucosamin®

IN COMBINATION
UNIQUE FORMULA
EVIDENCE BASED
IMPROVED PATIENT COMPLIANCE
NO SAFETY CONCERN

NEW TO CANADA!

Prevention and treatment of mucositis and dermatitis caused by radiotherapy, chemotherapy and combined treatments

“Please visit the HANSAMED booth to find out more”
Together Again: Connection, Reflection and Celebration

À nouveau réunis : connexions, réflexions, célébrations

OCTOBER 27-30, 2022
Victoria Convention Centre and Fairmont Empress Hotel